Dr. Min Huang is Co-Founder and Director of R&D at SWAN Genomics, a deep-tech biotech company pioneering a plasmonic nanoantenna-based single-molecule DNA sequencing platform spun out of UNSW Sydney.

Min earned a PhD in Nanobiotechnology from UNSW Sydney, a Master's in Oncological Pharmacology from Peking Union Medical College, and a Bachelor's in Pharmaceutical Science from China Pharmaceutical University, before serving as a Research Officer at UNSW.

As lead scientist on sequencing chemistry, polymerase engineering, and nanoantenna-based detection systems, Min drives SWAN's core technology development and has contributed to seven patent filings protecting the platform.

Prior to co-founding SWAN Genomics in 2023, Min held roles as a Project Manager and Deputy Department Manager at YaoPharma Co., Ltd., bringing pharmaceutical and biotech industry experience to complement her academic research background.

SWAN Genomics has raised over US$6M from investors including In-Q-Tel, Investible, and Proto Axiom, and is currently pursuing a Series A targeting AUD$20M+ to commercialise what it calls the world's first plasmonic nanoantenna-based sequencing platform.